Xilio Therapeutics, Inc. (XLO) - Q2 2024 10-Q Summary
Business Context and Reporting Period
Xilio Therapeutics, Inc. is a clinical-stage biotechnology company developing tumor-activated immuno-oncology therapies. This report covers the quarterly period ended June 30, 2024. The company is classified as a non-accelerated filer, a smaller reporting company, and an emerging growth company. As of August 1, 2024, there were 43,952,491 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|
| Total Revenue | $2.4 million | $2.4 million | $0 |
| Net Loss | $(13.9) million | $(31.1) million | $(42.0) million |
| Operating Expenses | $17.1 million | $34.5 million | $43.6 million |
| Cash and Cash Equivalents | $74.9 million (as of June 30, 2024) | ||
| Accumulated Deficit | $356.6 million (as of June 30, 2024) | ||
| Net Cash Provided by Operating Activities | $9.5 million (YTD 2024) |
Note: Revenue consists entirely of license revenue recognized from the Gilead Sciences agreement. The company has no product sales revenue.
Material Changes vs. Prior Period
- Revenue Recognition: The company recognized $2.4 million in license revenue for the three and six months ended June 30, 2024, compared to zero in the prior year periods. This stems from the March 2024 license agreement and stock purchase agreement with Gilead Sciences.
- Expense Reduction: Total operating expenses decreased by approximately $9.1 million year-over-year for the six-month period.
- R&D Expenses: Decreased by $7.7 million (from $29.3M to $21.6M), driven by reduced personnel costs, lower external preclinical expenses, and the discontinuation of monotherapy investment in XTX202.
- G&A Expenses: Decreased by $2.3 million (from $14.3M to $12.0M), primarily due to lower personnel and professional fees.
- Restructuring: The company incurred $1.0 million in restructuring charges during the first half of 2024 related to a workforce reduction of 15 employees (approx. 21% of the workforce) announced in March 2024.
- Debt Repayment: The company repaid all amounts outstanding under its $10.0 million loan agreement with Pacific Western Bank in the first quarter of 2024.
- Capital Raises: Proceeds from financing activities totaled $21.0 million YTD 2024, including private placements with Gilead and other investors, and at-the-market offerings.
Guidance, Outlook, and Risks
- Going Concern: The filing explicitly states there is substantial doubt about the company's ability to continue as a going concern. Management estimates current cash resources ($74.9 million) will fund operations only into the second quarter of 2025.
- Liquidity Strategy: To extend its runway, the company plans to raise additional capital through equity/debt financings, collaborations, or licensing. Failure to secure capital may necessitate further cost reductions or delays in R&D.
- Strategic Focus: The company is prioritizing the development of XTX101 (in collaboration with Roche) and XTX301 (licensed to Gilead). It discontinued further investment in XTX202 as a monotherapy.
- Key Risks:
- Dependence on the success of early-stage product candidates.
- Reliance on third-party CDMOs, including one in China, for manufacturing.
- Uncertainty regarding regulatory approvals and clinical trial outcomes.
- Potential dilution from future equity raises.
- Management Changes: On August 3, 2024, Christopher Frankenfield was appointed Chief Financial Officer and Chief Operating Officer.
Investor Verification Checklist
- Verify the timeline and sufficiency of the company's capital raise plans to bridge the gap beyond Q2 2025.
- Monitor the progress of the XTX101 Phase 1/2 trial with Roche and the XTX301 Phase 1 trial with Gilead.
- Review the terms of the Gilead agreement regarding the $75.0 million transition fee and potential milestone payments.
- Assess the impact of the recent workforce reduction on the company's ability to execute its clinical development plans.
- Track the company's compliance with Nasdaq listing requirements, specifically the minimum bid price, following the deficiency notice received in January 2024.